

ASX RELEASE

29 April 2022

ASX: NVU

Quarterly Activities Report and Appendix 4C for the Quarter Ended 31 March 2022

Highlights

- **Launch of Nanoshield™ Bot - a Robot as a Service (“RaaS”) based disinfection robot that dispenses a fine mist of the Company’s newly launched e-water, which contains Complex Oxygen Compounds with excellent antiviral and antibacterial efficacy¹.**
- **Nanoveu launched ‘Liquid Film’, a spray on version of the Company’s antimicrobial surface protection films, with the product achieving a >99.99% reduction of MHV-A59 (a surrogate for COVID-19) within 10 minutes².**
- **Liquid Film was listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses².**
- **Nanoshield™ Antiviral Liquid Spray listed by the Singapore National Environmental Agency (NEA) as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses².**
- **Nanoshield™ Antiviral Film product accepted as Class I medical device with the UK based Medicines and Healthcare products Regulatory Agency (MHRA).**
- **Mr David Nicol retired as a director of the Company.**

Nanoveu Limited (**ASX: NVU**) (“**Nanoveu**” or the “**Company**”) is pleased to provide an overview of activities to accompany the Appendix 4C for the quarter ended 31 March 2022 (“**Quarter**”, “**Reporting Period**”) including subsequent events that might have a significant impact between 31 March 2022 and the date of issuance of this Report.

Commenting on the Quarter, Nanoveu Founder & CEO, Alfred Chong, said: “The March 2022 Quarter was an important period for the Company, as we continued to advance our product development strategy with the launch of Nanoshield™ Bot, a Robot as a Service (“RaaS”) based disinfection robot which dispenses our newly launched e-Water. Having already been trialled at 5-star hotels, and with e-water being proven effective in eliminating coronavirus (SARS-CoV-2), we see significant potential for this product in Singapore, Asia and also globally.

“The March quarter also saw the launch of our Liquid Film, a spray on version of our antimicrobial surface coating, which allows Nanoveu to coat surfaces much faster including irregular shapes previously difficult to do using the existing Nanoshield™ films. During the Reporting Period, the

¹ Refer ASX announcement of 16 March 2022 for the testing performed and the results.

² Refer ASX announcement of 9 February 2022 for the testing performed and the results.



Liquid Film product was also listed by the Singapore NEA as a Self-Disinfecting Surface Coating Product Effective Against Coronaviruses.

“The Company’s Nanoshield™ Antiviral Film product was accepted as Class I medical device with the UK based Medicines and Healthcare products Regulatory Agency, with Nanoveu now able to market the Nanoshield™ product for a range of medical and non-medical applications in the United Kingdom.

“I would like to thank shareholders for their support to date, as we continue to develop and advance the Nanoveu suite of products.”

Nanoveu Launches Disinfection Robot Under a RaaS Model³

In March 2022, Nanoveu announced the launch of the Nanoshield™ Bot – a disinfection robot which kills viruses and bacteria using the Company’s new e-water; a chemical and alcohol-free formulation which is Halal certified.

e-water is a pH neutral sanitation water containing Complex Oxygen Compounds. It is food grade and not harmful to inhale, causes no eye or skin irritation, deodorises air, moisturises the skin, can be used with existing ultrasonic humidifier technology and passes Japanese tap water standards.

e-water is effective in eliminating coronavirus (SARS-CoV-2), inactivating 99.93% of SARS-CoV-2 (COVID-19) within 30 minutes, tested by Shokukanken Inc, Japan. Founded in 1998, Shokukanken is a full-service food testing and analysis laboratory operating in Maebashi City, Gunma, Japan. It is also effective in eliminating feline coronavirus within 30 seconds and Influenza A within 30 seconds.

e-water is made from a diaphragm free electrolytic cell method and vibrates molecules at a constant frequency to create ions that have strong antiviral efficacy, whilst maintaining pH neutrality.

Nanoshield™ Bot will be marketed and sold under the Nanoshield™ brand as a Robot as a Service (“RaaS”), whereby the Company will provide a complete solution including the supply of robot, maintenance, software management, the e-water disinfectant solution, public liability insurance and mapping.

The Nanoshield™ Bot was trialled at several five star hotels in Singapore including Resort World Sentosa & Ascott Hotel, with the trials including mapping, e-water and 3 day load period. Following the highly positive feedback received, there are currently a backlog of hotels awaiting trials, with Nanoveu to initially focus on the Singaporean market including hotels, hospitals, malls and airports with plans to expand into further jurisdictions. The recurring service fee is expected to provide a robust baseline of revenue for the Company.

Nanoveu Launches Durable Spray Coating Effective Against MHV-A59 (a Surrogate for COVID-19)⁴

During the Quarter, the Company announced the launch of ‘Liquid Film’, a spray-on version of the Company’s antibacterial and antiviral surface protection films, with the product achieving a >99.99% reduction of MHV (Murine coronavirus) within 10 minutes. MHV is listed by the Australian TGA as a preferred surrogate to justify effectiveness against COVID-19.

³ Refer ASX announcement of 16 March 2022 for the testing performed and the results.

⁴ Refer ASX announcement of 9 February 2022 for the testing performed and the results

From testing by the Department of Microbiology & Immunology, Yong Loo Lin School of Medicine at the National University of Singapore (NUS), Liquid Film (Spray) demonstrated 300 weeks of durability, making the Company's Liquid Film a market leading technology breakthrough.

The Liquid Film (Spray) allows the Company to coat surfaces much faster including irregular shapes previously difficult to do using the existing Nanoshield™ films.

Liquid Film has been approved by Singapore's NEA (National Environment Agency) as a self-disinfecting surface coating product effective against coronaviruses.

Nanoshield Accepted as Medical Device in the UK

During the Reporting Period, the Company received approval for the registration of its Nanoshield™ Film line as a Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) for the UKCA (UK Conformity Assessed) Mark.

Nanoshield™ is the only self-disinfecting coating registered as a Class 1 medical device in the UK. Nanoveu is now able to market the Nanoshield™ product for a range of medical and non-medical applications in the United Kingdom. As announced on 8 March 2022, the Company submitted the filing to the MHRA, with approval for the application being received in under 24 hours.

Nanoshield™ is intended to be applied to high touch surfaces of medical devices including, but not limited to, display screens of defibrillators and imaging devices to provide long lasting, continuous disinfection, reducing user-to-user touch cross-contamination thus assisting in prevention of disease. The applications within the Medical context can also include touch screens, handrails, trolleys, wheel chair handles and just about any high touch point.

Nanoshield™ Antiviral Liquid Spray NEA Listed⁵

As an after balance date event, Singapore's National Environment Agency (NEA) listed Nanoveu's Liquid Film as a self-disinfecting surface coating product effective against the COVID-19 virus after testing a total of 53 products. On 8 August 2021, Singapore's NEA listed the Nanoshield™ product as the first residual based product effective against coronavirus, creating a new category for Residual based products.

The listing of the Liquid Spray represents the third Nanoveu product listed by the NEA as a Self-Disinfecting Surface Coating Products Effective Against Coronaviruses, with Nanoshield™ film and Liquid Film / Spray also listed.

Liquid Spray is an alcohol free, eco-friendly, non-toxic, non-flammable and fragrance free spray that eliminates 99% of viruses and bacteria including coronavirus in 15 minutes and is effective for at least 6 months.

The listing of the Liquid Spray represents the third Nanoveu product listed by the NEA as a Self-Disinfecting Surface Coating Products Effective Against Coronaviruses. There are only 8 products listed in this category. Liquid Spray is an alcohol free, eco-friendly, non-toxic, non-flammable and fragrance free spray that eliminates 99% of viruses and bacteria including coronavirus in 15 minutes and is effective for at least 6 months.

Liquid Spray is the only Category A, NEA-listed product that is commercially available off-the-shelf and currently available for sale at Nanoveu's ecommerce site - www.nanoshield.com

⁵ Refer ASX announcement of 6 April 2022 for the testing performed and the results

Director Retirement

During the Quarter, Mr David Nicol retired as a director of the Company. Nanoveu thanks Mr Nicol for his service to the Company and wishes Mr Nicol all the best in retirement.

Expenditure

An Appendix 4C detailing expenditure for the quarter is appended. Payments to related parties totalling \$111k were paid during the quarter for directors' fees, executive remuneration, and pension / superannuation benefits.

The Company's focus has been the commercialization of its anti-viral products while also advancing research and development on the EyeFyx project.

Expenditure for the quarter ended 31 March 2022 included:

- Research and development expenditure of \$76k incurred in the research and development of new products, being mainly in relation to the Company's EyeFyx vision correction project;
- Product manufacturing and operating expenditure of \$17k incurred in producing products for sale, specifically the Company's anti-viral products, including the purchase and production of inventory for sale;
- Advertising and marketing expenditure of \$58k related to marketing the Company's anti-viral products;
- Staff costs of \$351k comprising the costs of all staff employed by the Company and directors' remuneration; and
- Administration and corporate costs of \$90k associated with running the Company, including ASX fees, audit fees, legal fees, share registry fees and rent.

- Ends -

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Scott Beeton
Non-executive Chairman
t: + 61 (0) 400 252 425
e: sbeeton@nanoveu.com

For media / investor enquiries, please contact:

Jane Morgan
Investor Relations
t: +61 (0) 405 555 618
e: info@janemorganmanagement.com.au

About Nanoveu Limited

We are technology innovators who specialize in modern, cutting-edge nanotechnology that improve the way we live, from reducing contagious transmissions on high touch points to immersive vision-based entertainment. <https://www.nanoveu.com/>

Nanoshield™ - is a film which uses a patented polymer of Cuprous embedded film to self-disinfect surfaces. Nanoshield™ antiviral protection which is available in a variety of shapes and forms, from mobile screen covers, to mobile phone cases and as a PVC commercial film, capable of being applied to several surfaces such as doorhandles and push panels. The perfectly clear plastic film contains a layer of charged copper nanoparticles which have antiviral and antimicrobial properties. This technology is also being applied to fabric applications targeting use in the personal protective equipment sector.

EyeFly3D - is a film applied to digital displays that allowed users to experience 3D without the need for glasses on everyday mobile handheld devices.

Customskins - are vending machines capable of precisely applying screen covers to mobile phones with an alignment accuracy of 150 microns.

EyeFyx - currently in research and development stage, EyeFyx is a vision correction solution using hardware and software to manipulate screen output addressing long-sightedness without the need to wear reading glasses.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Nanoveu Limited

ABN

97 624 421 085

Quarter ended ("current quarter")

31 March 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	71	71
1.2 Payments for		
(a) research and development	(76)	(76)
(b) product manufacturing and operating costs	(17)	(17)
(c) advertising and marketing	(58)	(58)
(d) leased assets	-	-
(e) staff costs	(351)	(351)
(f) administration and corporate costs	(90)	(90)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	9	9
1.8 Other (provide details if material)	4	4
1.9 Net cash from / (used in) operating activities	(508)	(508)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(70)	(70)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(70)	(70)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,013	2,013
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(508)	(508)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(70)	(70)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,435	1,435

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	158	302
5.2	Call deposits	1,277	1,712
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,435	2,013

**6. Payments to related parties of the entity and their
associates**

6.1 Aggregate amount of payments to related parties and their
associates included in item 1

6.2 Aggregate amount of payments to related parties and their
associates included in item 2

Current quarter \$A'000
111
-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
-	-
-	-
2,400	1,600
2,400	1,600

7.5 **Unused financing facilities available at quarter end**

800

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The Company has received \$1,600,000 for subscription for shares with the value of \$1,756,000 to be issued.

An additional \$800,000 subscription for shares with the value of \$878,000 may be made by mutual consent of the parties, subject to the Company obtaining shareholder approval for that subscription. Nanoveu has not agreed to issue any shares under this additional subscription and both parties may elect to mutually enter into this additional subscription at a future date. There is no obligation on Nanoveu to further enter into this additional subscription.

Each of these investments will be made by way of the Investor prepaying for Placement Shares. The Placement Shares in relation to all or part of each of the above investments will be issued upon the Investor's written request, within 18 months of the final subscription. The number of Placement Shares to be issued is to be determined by applying to the subscription amount prepaid by the Investor, with the Purchase Price equal to the average of the five daily volume-weighted average prices (rounded down to the next one tenth of a cent, or if the share price exceeds \$0.10, the next half a cent) during the 20 consecutive actual trading days immediately prior to the relevant Settlement Notice Date. Each issue of Placement Shares must be for no less than \$150,000 of the Placement Shares. The selection of the 5 days within the 20 trading days is at the discretion of the Investor.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(508)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	1,435
8.3 Unused finance facilities available at quarter end (Item 7.5)	800
8.4 Total available funding (Item 8.2 + Item 8.3)	2,235
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	4.4

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n/a

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n/a.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n/a

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

29 April 2022

Date:

Managing Director and CEO

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.